ReviewNature reviews. Drug discovery2015
Managing diabetes with nanomedicine: challenges and opportunities.
Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Design strategies for chemical-stimuli-responsive programmable nanotherapeutics.Drug discovery today · 2019Pooled it
- Clinical validation of continuous glucose monitoring in glycemic management of critically ill sepsis patients: A prospective randomized clinical study.The Journal of international medical research · 2026Trial
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Insulin Encapsulation in a Chitosan-Alginate Matrix and In Vitro Release.Bioengineering (Basel, Switzerland) · 2026Article
- Electrically Modulated Semi-Convertible Hydrogel Microneedles for Programmable Insulin Delivery.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.Biomedical microdevices · 2026Article
- From conceptual design to translational progress: Emerging advances in intelligent microneedles for biomedical applications.Acta pharmaceutica Sinica. B · 2026Review
- Vertical graphene-coated core-shell microneedle as miniatured sensor for in vivo glucose monitoring.Microsystems & nanoengineering · 2026Article
- [Advances in injectable and transdermal glucose-responsive insulin delivery systems].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Engineering combination nanomedicines to overcome cancer resistance.RSC advances · 2026Review
- Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.AAPS PharmSciTech · 2025Review
- Integrated individually addressable microneedle arrays for robust glucose monitoring and on-demand insulin releasing.Microsystems & nanoengineering · 2025Article
- Site-specific adaptive nanovesicles for oral insulin delivery.Science advances · 2025Article
- Multifunctional hydrogel with mild photothermal properties enhances diabetic wound repair by targeting MRSA energy metabolism.Journal of nanobiotechnology · 2025Article
- Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design.ACS materials Au · 2025Review
- Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.Current diabetes reviews · 2025Review
- Diabetology and Nanotechnology: A Compelling Combination.Recent patents on nanotechnology · 2025Review
- Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes.Frontiers in endocrinology · 2025Review
- Targeting oxidative damage in diabetic foot ulcers: integrative strategies involving antioxidant drugs and nanotechnologies.Burns & trauma · 2025Review
- Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects.International journal of nanomedicine · 2025Review
132 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are also providing the basis for glucose-responsive nanoparticles that better mimic the body's physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 diabetes. Here, we analyse the current state of these approaches and discuss key issues for their translation to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.